侯旭奔，博士，副研究員，碩士生導師，入選山東大學青年學者未來計劃。主要從事藥物化學和藥物分子設計研究，通過發展多尺度的計算策略進行基于靶點結構的藥物設計和高通量虛拟篩選，并對活性先導化合物進行結構優化和生物活性評價。近年來以第一作者/通訊作者發表SCI論文20餘篇，相關成果發表在J. Med. Chem.,J. Chem. Inf. Model., J. Biol. Chem. Eur. J. Med. Chem.,等領域權威期刊上。目前，主持國家自然科學基金、山東省自然科學基金、橫向課題、國際合作課題等多個科研項目。

聯系方式：

Email: hxb@sdu.edu.cn

Tel: 0531-88380720

通訊地址：山東省濟南市文化西路44号山東大學趵突泉校區

學習及工作經曆

• 2007.9- 2011.6推荐几个网赌网站，藥學專業，學士

• 2011.8-2012.8共青團中央-山東大學研究生支教團（西部計劃）

• 2012.9- 2017.6推荐几个网赌网站，藥物化學專業，碩博連讀（導師：方浩教授）

• 2015.10-2017.4紐約大學化學系，訪問學者（導師：Prof. Yingkai Zhang）

• 2017.7- 2018.8紐約大學化學系，博士後（導師：Prof. Yingkai Zhang）

• 2018.12-至今推荐几个网赌网站，副研究員

  研究方向

• 調控蛋白翻譯後修飾相關靶點的藥物設計、合成與生物活性研究。

• 靶向蛋白-蛋白相互作用的新型小分子調控劑的設計、合成與生物活性研究

• 基于分子力學、量子力學、人工智能算法發展靶點特異性的藥物設計策略。

  主持科研項目

• 新型LYP變構抑制劑的發現、優化以及抗自身免疫性疾病活性研究，國家自然科學基金青年科學基金項目（82003590）

• 新型蛋白酪氨酸磷酸酶選擇性抑制劑的合理設計、合成與生物活性研究，山東省自然科學基金青年科學基金項目（ZR2020QH342）

• 山東大學青年學者未來計劃（2019-2024）

• 山東大學中澳健康科學研究中心合作研究項目

• 山東大學-卡羅林斯卡醫學院國際合作項目

• 企業橫向

  發表論文情況

1. Chen C, Li X, Zhao H, Liu M, Du J, Zhang J, Yang X,Hou X*, Fang H*. Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.J. Med. Chem.2022, 65(4):3667-3683.

2. Liang H, Zhu Y, Zhao Z, Du J, Yang X,Fang H*,Hou X*. Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer.Front. Pharmacol.2022, 13: 864342.

3. Liang X, Li X, Zhao Z, Nie Y, Yao Z, Ren W, Yang X,Hou X*, Fang H*. Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors.Bioorg. Chem.2022, 121:105643.

4. Liu M, Gao S, Elhassan RM,Hou X*, Fang H*. Strategies to overcome drug resistance using SHP2 inhibitors.Acta Pharm. Sin. B. 2021,11(12):3908-3924.

5. Elhassan RM,Hou X*, Fang H*. Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discovery.Med. Res. Rev.2022, 42(3):1064-1110.

6. Hou X, Du J*, Fang H*. PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer.J. Cancer.2021, 12(24):7445-7453.

7. Teng KW, Tsai ST, Hattori T, Fedele C, Koide A, Yang C,Hou X, Zhang Y, Neel BG, O'Bryan JP, Koide S. Selective and noncovalent targeting of RAS mutants for inhibition and degradation.Nat Commun.2021, 12(1):2656.

8. Hou X, et al. Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed cryptic pockets,Eur. J. Med. Chem., 2020,190:112131.

9. Liu L, Liu R, Yang X,Hou X*, Fang H*. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.Eur. J. Med. Chem.,2020, 191:112142.

10. Liang X, Fu H, Xiao P, Fang H*,Hou X*. Design, synthesis and biological evaluation of imidazolidine-2,4-dione and 2-thioxothiazolidin-4-one derivatives as lymphoid-specific tyrosine phosphatase inhibitors.Bioorg. Chem.,2020, 103:104124.

11. Du J, Liu L, Liu B, Yang J,Hou X*, Yu J*, Fang H*. Structure-based virtual screening, biological evaluation and biophysical study of novel Mcl-1 inhibitors.Future Med. Chem.,2020,12(14):1293-1304.

12. Du J, Li W, Liu B, Zhang Y, Yu J,Hou X*,Fang H*. An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators.Bioorg. Med. Chem.,2020, 28(16):115607.

13. Lu J,Hou X, Wang C, Zhang Y. Incorporating Explicit Water Molecules and Ligand Conformation Stability in Machine-Learning Scoring Functions.J. Chem. Inf. Model.2019, 59(11):4540-4549.

14. Chen C, Nie Y, Xu G, Yang X, Fang H,Hou X*. Design, synthesis and preliminary bioactivity studies of indomethacin derivatives as Bcl-2/Mcl-1 dual inhibitors.Bioorg. Med. Chem.2019, 27(13):2771-2783.

15. Chen C, Yang X, Fang H*,Hou X*. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.Eur. J. Med. Chem.2019, 181:111563.

16. Li K#,Hou X#, Li R#, Bi W#, Yang F, Chen X, Xiao P, Liu T, Lu T, Zhou Y, Tian Z, Shen Y, Zhang Y, Wang J, Fang H, Sun J*, Yu X.* Identification and structure-function analyses of an allosteric inhibitor of the tyrosine phosphatase PTPN22.J. Biol. Chem.2019, 294(21):8653-8663.

17. Hou X, Rooklin D, Yang D, Liang X, Li K, Lu J, Wang C, Xiao P, Zhang Y, Sun JP, Fang H. Computational Strategy for Bound State Structure Prediction in Structure-Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitors.J. Chem. Inf. Model.2018, 58(11):2331-2342.

18. Hou X, et al. Resveratrol serves as a protein-substrate interaction stabilizer in human SIRT1 activation.Sci. Rep.,2016,6, 38186.

19. Hou X, et al. Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures.J. Chem. Inf. Model.2015, 55(9):1973-1983.

20. Hou X, et al. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8.J. Chem. Inf. Model.2015, 55(4):861-871.

21. Hou X, et al. Fast Identification of Novel Lymphoid Tyrosine Phosphatase Inhibitors Using Target-Ligand Interaction-Based Virtual Screening.J. Med. Chem.2014, 57, 9309-9322.

22. Hou X, et al. How to improve docking accuracy of AUTODOCK4.2: A case study using different electrostatic potentials.J. Chem. Inf. Model.2013, 53(1):188-200.

    獲獎情況

    《藥學學報》藥學前沿論壇青年論壇優秀論文三等獎

    山東大學青年教師講課比賽二等獎、三等獎

    山東大學青年教師講課比賽青年教學能手

    全國藥物化學學術會議優秀牆報獎

    山東省研究生優秀科技創新成果獎

    山東省優秀共青團員

    “挑戰杯”全國大學生課外學術科技作品競賽二等獎

    中國專利年會“校園發明與創新”金獎

    學術兼職情況

    Eur. J. Med. Chem., Theranostics, Bioorg. Chem., Bioorg. Med. Chem., Phys. Chem. Chem. Phys.等雜志審稿人

    Member of The New York Academy of Sciences

    中國藥學會會員,中國化學會會員